Search results
PTC Stock Surges 41% in a Year: Will the Rally Continue?
Zacks· 1 day agoFree Report) is continuing its upward trajectory, with a gain of 41% in the past year compared with the S&P 500 composite and sub-industry’s growth of 29.2% and 35.7%, respectively.
PTC Therapeutics (NASDAQ:PTCT) PT Raised to $53.00
ETF DAILY NEWS· 1 day agoPTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its target price boosted by JPMorgan Chase & Co. from $43.00 to $53.00 in a note issued to investors on Tuesday, Benzinga ...
PTC Inc. (NASDAQ:PTC) Holdings Lifted by BI Asset Management Fondsmaeglerselskab A S
ETF DAILY NEWS· 1 day agoBI Asset Management Fondsmaeglerselskab A S boosted its position in shares of PTC Inc. (NASDAQ:PTC – Free Report) by 36.0% in the 4th quarter, according ...
News Flash: Analysts Just Made A Notable Upgrade To Their PTC Therapeutics, Inc. (NASDAQ:PTCT)...
Simply Wall St. via Yahoo Finance· 2 days agoPTC Therapeutics, Inc. (NASDAQ:PTCT) shareholders will have a reason to smile today, with the...
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
Zacks via Yahoo Finance· 3 days agoPTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP...
Analysts review PTC Inc’s rating – Knox Daily
Knox Daily· 3 days agoIn a filing, PTC Inc revealed its Director Lathan Corinna unloaded Company’s shares for reported $0.34 million on May 09 ’24. In the deal valued at $179.39 per share,1,901 ...
Kentucky Retirement Systems Decreases Stock Holdings in PTC Inc. (NASDAQ:PTC)
ETF DAILY NEWS· 4 days agoKentucky Retirement Systems lessened its holdings in PTC Inc. (NASDAQ:PTC – Free Report) by 4.6% during the 4th quarter, according to its most recent disclosure ...
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
Investor's Business Daily· 4 days agoPTC stock hit a nine-month high Monday after the European Commission decided against pulling its...
PTC Therapeutics stock target raised on re-evaluation of Translarna By Investing.com
Investing.com· 4 days agoOn Monday, Jefferies maintained a Buy rating on PTC Therapeutics (NASDAQ:PTCT) and increased the...
European Commission, in ‘unprecedented’ move, declines to revoke approval of PTC Duchenne drug
BioPharma Dive via Yahoo Finance· 4 days agoRather than endorse the recommendation of the EMA, the commission called for a new review for...
